Expression Pathology, Inc.;Memorial Sloan-Kettering Cancer Center
发明人:
Todd HEMBROUGH,Fabiola CECCHI,Sarit SCHWARTZ,Maurizio SCALTRITI,Bob T. LI
申请号：
US16617580
公开号：
US20200103411A1
申请日:
2018.06.04
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Improved methods for treating lung cancer are provided. Tumor samples from patients are analyzed (i) by DNA sequencing to detect the presence of HER2 mutations and (ii) by mass spectrometric proteomic analysis to determine whether HER2 protein is expressed in the tumor cells. Patients respond to therapy with trastuzumab emtansine (T-DM1) or an equivalent antibody-drug conjugate when unique HER2 protein fragments are detected in the patient's tumor cells that harbor HER2 mutations. Conversely, patients do not respond to T-DM1 therapy when the tumor cells contain HER2 mutations but the unique protein fragments are not detected. Detection of HER3 in the tumor cells is a positive predictor of response to treatment.
